A widely available antidepressant holds promise as a treatment for Covid-19, according to a new study.
Covid-19 patients who received fluvoxamine were significantly less likely to require hospitalization than those who didn’t, in the largest clinical trial evaluating the antidepressant’s effect on Covid-19 to date.